AR786

AR786 is a **selective small-molecule inhibitor of tropomyosin receptor kinase A (TrkA)**, the primary receptor for nerve growth factor (NGF). By inhibiting TrkA, AR786 blocks NGF-mediated nociceptor sensitization, resulting in a reduction of pain and inflammation in preclinical models. It was developed for potential use in conditions characterized by chronic pain and inflammation, such as osteoarthritis and inflammatory arthritis. AR786 shows oral bioavailability and has been studied predominantly in animal models, where it effectively reduced pain behavior, synovitis, and in some cases, joint pathology. The drug appears to modulate neural ingrowth into injured tissues and suppress trauma-induced heterotopic ossification. It has not advanced to human clinical trials as of the latest reports, and its development is mainly academic with The University of Nottingham as a lead institution[1][3][5][7][9].